Miguel Canales

Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study

Lihua E. Budde, Laurie H. Sehn, Matthew J. Matasar et al. · The Lancet Oncology · 2022 · 390 citations

Lymphoid Neoplasia, Bispecific Antibody, Medicine +7

Selinexor in patients with relapsed or refractory diffuse large B-cell lymphoma (SADAL): a single-arm, multinational, multicentre, open-label, phase 2 trial

Nagesh Kalakonda, Marie Maerevoet, Federica Cavallo et al. · The Lancet Haematology · 2020 · 324 citations · Full text

Hematological Malignancy, Lymphoid Neoplasia, Medicine +4

Classification, prevalence, and outcomes of anticancer therapy-induced cardiotoxicity: the CARDIOTOX registry

José López‐Sendón, Carlos Álvarez-Ortega, Pilar Auñón et al. · European Heart Journal · 2020 · 266 citations · Full text

Impact of hematologic malignancy and type of cancer therapy on COVID-19 severity and mortality: lessons from a large population-based registry study

Julio García‐Suárez, Javier de la Cruz, Ángel Cedillo et al. · Journal of Hematology & Oncology · 2020 · 238 citations · Full text

Immunochemotherapy With Obinutuzumab or Rituximab for Previously Untreated Follicular Lymphoma in the GALLIUM Study: Influence of Chemotherapy on Efficacy and Safety

Wolfgang Hiddemann, Anna Maria Barbui, Miguel Canales et al. · Journal of Clinical Oncology · 2018 · 226 citations · Full text